Form 4: Icahn School of Medicine at Mount Sinai Sells 865,800 Shares of GeneDx Holdings Corp.

Icahn School of Medicine at Mount Sinai, a 10% owner of GeneDx Holdings Corp., disposed of 865,800 shares of Class A Common Stock on October 31, 2024, at a price of $75 per share.

Summary

• On October 31, 2024, Icahn School of Medicine at Mount Sinai sold 865,800 shares of GeneDx Holdings Corp.'s Class A Common Stock.
• The sale price was $75 per share.
• Following the transaction, Icahn School of Medicine at Mount Sinai directly holds 2,866,833 shares of GeneDx Holdings Corp.
• Mount Sinai Health System, Inc. is the sole member of Icahn School of Medicine at Mount Sinai.
• All share amounts reflect the 33:1 reverse stock split of the Issuer's Class A common stock effective May 4, 2023.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. A large shareholder selling a significant portion of their holdings can be perceived negatively by the market, although the filing itself is a routine disclosure.

Negatives

• A significant shareholder, Icahn School of Medicine at Mount Sinai, has reduced its stake in GeneDx Holdings Corp. by selling 865,800 shares.

Risks

• The sale of a large number of shares by a significant shareholder could potentially exert downward pressure on the stock price.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or significant shareholders of a publicly traded company buy or sell the company's stock. These filings provide transparency into the transactions of those with privileged information and can influence investor sentiment.

Stakeholder Impact

• Shareholders may react to the news of a large share sale by a significant shareholder.
• The market price of GeneDx Holdings Corp. stock could be affected by this transaction.

Key Dates